On December 9, 2024, the new patient guideline on myasthenic syndromes was published in the AWMF guideline register. This guideline was developed in collaboration between the German Brain Foundation (DHS), the German Society of Neurology (DGN) and the German Myasthenia Society (DMG). Based on the scientific “S2k guideline on the diagnosis and treatment of myasthenic syndromes”, it translates complex medical findings into understandable language that is specifically tailored to the needs of patients and their caregivers.
Why a patient guideline?
The diagnosis and treatment of rare diseases such as myasthenia gravis, Lambert-Eaton myasthenic syndrome (LEMS) or congenital myasthenic syndromes (CMS) is often complex. This makes it all the more important that those affected and their relatives have access to reliable information to support them in dealing with the condition.
The patient guideline explains the scientific principles of the specialist guideline in easy-to-understand terms and provides concrete assistance for everyday life. Particularly valuable: it was developed with the close involvement of myasthenia specialists and patient representatives. This ensures that the content is both technically sound and practical and user-friendly.
More support and self-determination
The aim of the guideline is to help patients better understand their condition and make confident, informed decisions. It provides orientation and practical tips for coping well with everyday life with a myasthenic disorder.
The new patient guideline is a valuable resource for anyone affected by myasthenia gravis, LEMS or CMS.
You can find more information on the DMG website: https://dmg.online/2024/12/12/leitlinie-zu-myasthenen-syndromen-fuer-patientinnen-und-patienten-verfuegbar/